The Centre for Process Innovation (CPI) in England has launched a £26.4 million ($32 million) plant named the RNA Centre of Excellence, which will facilitate the production of RNA products for early-stage clinical trials. The facility can potentially manufacture 100 million vaccines a year during emergencies. This first-of-its-kind center in the UK can produce messenger and self-amplifying RNA vaccines and therapies. CPI, launched by the government in 2004, bridges the gap between academia, investors, and companies for turning ideas and research into marketable products. The RNA Centre of Excellence is involved in several projects, including collaboration with VaxEquity on the first saRNA flu vaccine. Despite previously failed endeavors in vaccine production, the new center, funded by the Department for Science, Innovation and Technology, aims to bolster the UK’s vaccine resilience.
To read more, click here.
[Source: Fierce Biotech, September 25th, 2023]